Key Points
- Gregory Lucier, a Maravai director, bought 48,528 shares on Dec. 8 at $3.67 each (~$178,098), boosting his holdings to 155,123 shares — a 45.53% increase — as disclosed in an SEC Form 4 filing.
- Maravai reported a quarterly loss (EPS -$0.08) that missed estimates and revenue of $41.63M vs. $49.02M expected, with a negative net margin (-62.88%) and negative P/E; the stock trades near $3.69 with a 52-week range of $1.66–$6.21 and market cap ~ $944M.
- Analyst coverage is mixed (average rating "Hold" and average target $5.36), and institutional investors own about 50.25% of the company, with several funds recently initiating or increasing positions.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) Director Gregory Lucier purchased 48,528 shares of the firm's stock in a transaction that occurred on Monday, December 8th. The stock was acquired at an average price of $3.67 per share, for a total transaction of $178,097.76. Following the completion of the purchase, the director directly owned 155,123 shares of the company's stock, valued at $569,301.41. This represents a 45.53% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Maravai LifeSciences Price Performance
NASDAQ:MRVI opened at $3.69 on Wednesday. Maravai LifeSciences Holdings, Inc. has a 52 week low of $1.66 and a 52 week high of $6.21. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.56 and a current ratio of 5.29. The firm's 50-day simple moving average is $3.34 and its 200 day simple moving average is $2.77. The firm has a market cap of $943.56 million, a price-to-earnings ratio of -4.39 and a beta of 0.32.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.02). Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%.The business had revenue of $41.63 million for the quarter, compared to analyst estimates of $49.02 million. As a group, sell-side analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current year.
Institutional Investors Weigh In On Maravai LifeSciences
A number of large investors have recently modified their holdings of the business. Nuveen LLC bought a new position in shares of Maravai LifeSciences in the first quarter worth about $666,000. Philosophy Capital Management LLC bought a new stake in shares of Maravai LifeSciences during the 1st quarter valued at approximately $5,731,000. Jacobs Levy Equity Management Inc. increased its position in Maravai LifeSciences by 437.0% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 493,582 shares of the company's stock worth $1,091,000 after purchasing an additional 401,673 shares in the last quarter. Strs Ohio bought a new position in Maravai LifeSciences in the 1st quarter valued at approximately $429,000. Finally, Parkman Healthcare Partners LLC lifted its stake in Maravai LifeSciences by 88.6% in the 1st quarter. Parkman Healthcare Partners LLC now owns 660,000 shares of the company's stock valued at $1,459,000 after purchasing an additional 310,000 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company's stock.
Wall Street Analysts Forecast Growth
MRVI has been the topic of a number of analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Royal Bank Of Canada cut their target price on Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a research report on Tuesday, August 12th. Three investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Maravai LifeSciences presently has an average rating of "Hold" and an average target price of $5.36.
View Our Latest Report on Maravai LifeSciences
About Maravai LifeSciences
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
